Skip to main content
. 2018 Dec 19;13(12):e0208240. doi: 10.1371/journal.pone.0208240

Fig 1.

Fig 1

Percentage for ever-use of A) DMARDs, B) TNF-inhibitors, C) steroids, and D) methotrexate among Arab rheumatoid arthritis patients across five country sites.